MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
0.3735
-0.0086
-2.25%
After Hours: 0.3804 +0.0069 +1.85% 19:01 11/27 EST
OPEN
0.4000
PREV CLOSE
0.3821
HIGH
0.4050
LOW
0.3552
VOLUME
875.37K
TURNOVER
0
52 WEEK HIGH
3.758
52 WEEK LOW
0.2911
MARKET CAP
66.15M
P/E (TTM)
-0.2602
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SGMO last week (1120-1124)?
Weekly Report · 1d ago
Gene editing stocks slide after two-day rally
Gene editing stocks slide after two-day rally after two straight sessions of strong gains. Last week's rally followed the u.k. Approval of a crispr-based gene editing drug. Spdr s&p biotech etf has lost 2% on tuesday.
Seeking Alpha · 6d ago
Weekly Report: what happened at SGMO last week (1113-1117)?
Weekly Report · 11/20 09:25
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shapeways holdings, inc. Shares fell 20.8% to $2.36 on wednesday. Shapeways reported downbeat quarterly sales of $8.37 million. Taysha gene therapies shares climbed 62.4% after the company reported third-quarter results.
Benzinga · 11/15 19:04
Weekly Report: what happened at SGMO last week (1106-1110)?
Weekly Report · 11/13 09:24
Strategic Reorganization and Potential Partnerships Drive Buy Rating for Sangamo Biosciences: An Analysis by Ritu Baral
TipRanks · 11/08 01:15
Truist Securities Downgrades Sangamo Therapeutics to Hold
Benzinga · 11/07 13:04
Where Sangamo Therapeutics Stands With Analysts
9 analysts have published their opinion on sangamo therapeutics over the past 3 months. sangamo has an average price target of $5.22 with a high of $10.00 and a low of $1.00. according to 9 analyst offering 12-month price targets in the last 3 months, sangamo is a buy.
Benzinga · 11/06 21:00
More
About SGMO
Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; TX200, its wholly owned Chimeric Antigen Receptor (CAR), engineered regulatory T cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A., and BIVV003, its zinc finger nuclease, or ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD).

Webull offers Sangamo Therapeutics Inc stock information, including NASDAQ: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.